

6/17/04

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (B&W No. 003979-00002)

Applicant:

Weaver, et al.

Serial No.:

10/800,587

Filing Date:

March 15, 2004

Examiner:

Unassigned

Group:

3763

Conf. No.:

1652

Title:

MICROSCISSION PROCESS AND PROCEDURE

CERTIFICATE OF EXPRESS MAIL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Express Mail Receipt No. <u>EV436814039US</u>

Date of Deposit: June 16, 2004

I hereby state that the following:

- **X** Information Disclosure Statement
- **X** PTO-1449 Form
- X Copies of Art as Cited on Page 1-2 of PTO-1449 Form
- X Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, on the date indicated above and is addressed to Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brigid Laffey

June 16, 2004

Dated

Brond Lapley

Signature of person mailing above-identified papers



Docket No. 003979/00002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Weaver, et al.

EXAMINER: Unassigned

SERIAL NO.:

10/800,587

GROUP:

3763

FILED:

15 March 2004

CONF. NO.: 1652

FOR:

Microscission Process and Procedure

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56 and §1.97, Applicant herewith submits the publications and/or patents shown on the attached Form PTO-1449, for consideration by the Examiner in connection with the examination of the aboveidentified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits

It is respectfully requested that each of the documents shown on the attached form PTO-1449 be made of record in this application. Copies of these documents are in the file of related application Serial No. 09/878,155, filed 07 June 2001 and are thus not being resubmitted herein.



Information Disclosure Statement U.S.S.N. 10/800,587 Page 2 of 2

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Any fee associated with this submission should be charged to our Deposit Account - No. 19-0733.

CERTIFICATE OF EXPRESS MAIL FILING

The undersigned hereby certifies that this correspondence is being deposited by Express Mail, Express Mail Receipt No. EV 436814039 in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 16, 2004.

Respectfully submitted,

Ernest V. Linek (Reg. No. 29,822)

Áttorney for Applicant

BANNER & WITCOFF, LTD. 28 State Street, 28th Floor

Boston, MA 02109-1775

Tel: (617) 720-9600

Fax: (617) 720-9600

E-mail: ELinek@bannerwitcoff.com

Date: 16 June 2004

JUN 1 6 2004

Sheet

PADI PADI

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BM/ PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO MFORMATION DISCLOSURE STATEMENT BY APPLICANT

> of 8

(use as many sheets as necessary)

Complete if Known 10/800,587 **Application Number** Filing Date March 15, 2004 James C. Weaver First Named Inventor Art Unit 3763 **Examiner Name** Not Yet Assigned 003979-00002 Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner	. Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	5.105 503 713 71	Passages or Relevant Figures Appear
		US- 6,706,032	03/16/2004	James C. Weaver et al.	
		US-			

	FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	۳°	
		WO 01/93947 A1	12/13/01	James C. Weaver et al.			

	Examiner Signature	/Bhisma Mehta/	Date Considered	06/01/2009	
--	-----------------------	----------------	--------------------	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BM/

PTO/SB/08b(05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

2

NITORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

8

of

 Complete if Known

 Application Number
 10/800,587

 Filing Date
 March 15, 2004

 First Named Inventor
 James C. Weaver

 Group Art Unit
 3763

 Examiner Name
 Not Yet Assigned

 Attorney Docket Number
 003979-00002

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
		TERRY O HERNDON et al., Transdermal microconduits by microscission for drug delivery and sample acquisition, BMC Medicine 2004, 2:12, April 19, 2004				
_						

Examiner Signature	/Bhisma Mehta/	Date Considered	06/01/2009	
-----------------------	----------------	--------------------	------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUN 1 6 2004

PHATE TOANS

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BM/

UNSIDERED EXCEPT WHERE LINED THROUGH. /BM/
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known titute for form 1449A/PTO Application Number 10/800,587

IN ORMATION DISCLOSURE ATEMENT BY APPLICANT

(use as many sheets as necessary)

of 8 Sheet 3

Filing Date March 15, 2004 James C. Weaver First Named Inventor Art Unit 3763 **Examiner Name** Not Yet Assigned 003979-00002 Attomey Docket Number

			U.S.	PATENT DOCUMENTS				
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING IF APPROP	r ·
	AC2	5,630,796	20 May 97	Bellhouse, et al.	604	49		
				·				
						,		
<u></u>			<u> </u>					
				·				
		<u> </u>				- 1		
	<u> </u>					 		
 	<u> </u>					 		
		·	<u> </u>					
			TODRIC	N PATENT DOCUMENTS		L	<u> </u>	
			·	COUNTRY	CLASS	SUB- CLASS	TRANSL	ATION NO
	-	DOCUMENT NUMBER	DATE	PCT	1			
	AM	WO 00/03758	27 Jan 00	PCT				
	AN	WO 97/04832	13 Feb 97					
	AO	EO 0 417 290	20 Mar 91	EPO				
	AP		ļ			-		
	QA							
	<u> </u>							
	 	OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertine	nt Pages,	EtC.)	<u> </u>	
	AR							
	AS							
	AT					_		
EXAM	INER	/Bhisma Mehta/		DATE CONSIDERED 06/01	/2009			

PTO/SB/08a (05-03)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /BM/Approved for use through 04/30/2003. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

JUN 1 6 2014 ATTATEMENT BY APPLICANT

(use as many sheets as necessary)

	·	Complete If Known	
	Application Number	10/800,587	
	Filing Date	March 15, 2004	
	First Named Inventor	James C. Weaver	
i	Art Unit	3763	
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number	003979-00002	

		1	1				
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DAT
	AA	5,019,034	05/28/1991	Weaver, et al.	604	20	
	AB	5,389,069	02/14/1995	Weaver	604	21	
	AC	6,085,115	07/04/2000	Weaver, et al.	600	509	
	AD	5,003,987	04/02/1991	Grinwald	128	734	
	AE	5,688;233	11/18/1997	Hofmann, et al.	604	20	
	AF	5,885,211	03/23/1999	Eppstein, et al.	600	309	
	AG	6,142,939	11/07/2000	Eppstein, et al.	600	309	
	АН	6,022,316	02/08/2000	Eppstein, et al.	600	309	
	AI	5,547,467	08/20/1996	Pliquett, et al.	604	20 %	
	ΑĴ	5,667,491	09/16/1997	Pliquett, et al.	604	50	
	AK	5,749,847	05/12/1998	Zewert, et al.	604	49	
	AA2	5,911,223	06/15/1999	Weaver, et al.	128	898	
	AB2	5,983,131	11/09/1999	Weaver, et al.	604	20	
			FOREIGN	PATENT DOCUMENTS	·		<u> </u>
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 97/07734	03/06/1997	PCT			
		OTHER DOCUMENTS	(Including Auth	or, Title, Date, Pertinent	Pages, i	Stc.)	
	AR	Langer, R., "Dru	g Delivery a	nd Targeting.," Natur	e, 392:	S5-S10	(1998).
	AS			neous Transport in Re Composition," <i>J. Inve</i>			
	AT	Elias, P.M., and Correlates of th 1-26 (1991).	Menon, G.K. e Epidermal	, "Structural and Lip Permeability Barrier,	id Bioc	hemical Lipid R	es., 24:
	UA	Zewert, T.E., et al., "Creation of Transdermal Pathways for Macromolecule Transport by Skin Electroporation and a Low Toxicity, Pathway-Enlarging Molecule," Bioelectrochem. and Bioenerget., 49:11-20 (1999).					
	AV	Ilic, L., et al., "Electrochemical Creation of Microconduits in Full-Thickness Human Skin for Transdermal Drug Delivery by Pressure-Driven Flow," Proc. Internat. Symp. on Controlled Release of Bioact. Materials, Controlled Release Society, 26:178-179 (1999).					
XAMIN	IER	/Bhisma Mehta/	<u> </u>	DATE CONSIDERED	· · · · · · · · · · · · · · · · · · ·		

Receipt date: 06/16/2004

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BM/Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/800,587 INFORMATION DISCLOSURE Filing Date March 15, 2004 TATEMENT BY APPLICANT First Named Inventor James C. Weaver Art Unit 3763 (use as many sheets as necessary) Examiner Name Not Yet Assigned of Attorney Docket Number 003979-00002

"	
	U.S. PATENT DOCUMENTS
ļ	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
A	Ilic, L., et al., "Spatially Constrained Skin Electroporation with Sodium Thiosulfate and Urea Creates Transdermal Microconduits," J. Control. Release, 61:185-202 (1999)
AX	Yamashita, N., et al., "Scanning Electron Microscopic Evaluation of the Skin Surface after Ultrasound Exposure," The Anatomical Record, 247: 455-461 (1997).
AY	Tachibana, K., and Tachibana, S., "Transdermal Delivery of Insulin by Ultrasonic Vibration," J. Pharm. Pharmacol., 43(4):270-271 (1991).
, AZ	Mitragotri, S., et al., "Ultrasound-Mediated Transdermal Protein Delivery," Science, 269:850-853 (1995).
AR	Mitragotri, S., et al., "Determination of Threshold Energy Dose for Ultrasound-Induced Transdermal Drug Transport," J. Controlled Release, 63:41-52 (2000).
AS:	Jacques, S.L., et al., "Controlled Removal of Human Stratum Corneum by a Pulsed Laser," J. Invest. Dermatol., 88(1):88-93 (1987).
AT	Nelson, J.S., et al., "Mid-Infrared Laser Ablation of Stratum Corneum Enhances in Vitro Percutaeous Transport of Drugs," J. Invest. Dermatol., 97(5):874-879 (1991).
AU2	Eisenbraun, M.D., et al., "Examination of Parameters Affecting the Eliciation of Humoral Immune Responses by Particle Bombardment-Mediated Genetic Immunization," DNA and Cell Biology, 12(9):791-797 (1993).
AV2	
AW2	
- AX2	Cullander, C., "What Are the Pathways of Iontophoretic Current Flow Through Mammalian Skin?" Adv. Drug Delivery Rev., 9(2/3):119-135 (1992).
AY2	Inada, H., et al., "Studies on the Effects of Applied Voltage and Duration on Human Epidermal Membrane Alteration/recovery and the Resultant Effects upon Iontophoresis," Pharm. Res., 11(5):687-697 (1994).
AZ2	Green, P.G., "Iontophoretic Delivery of Peptide Drugs," J. Controlled Release, 41:33-48 (1996).
EXAMINER	

1 HUL

PTO/SB/08a (05-03)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BM/oved for use through 04/30/2003. OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUN 1

Complete if Known Application Number 10/800,587 Filing Date March 15, 2004 First Named Inventor James C. Weaver Art Unit 3763 Examiner Name Not Yet Assigned Attorney Docket Number 003979-00002

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) of

		OTHER DOCUMENTS (Including Aut	hor, Title, Date, Pertinent Pages, Etc.)		
	AR3	Merino, V., et al., "Transd Iontophoresis," TIBTech., 1	ermal Therapy and Diagnosis by 5:288-290 (1997).		
	AS3	Dinh, S.M., et al., "Upper Resistance in Iontophoresis	and Lower Limits of Human Skin Electrical ," AIChE J., 39(12) :2011-2018 (1993).		
	ETA	Iontophoretic Drug Delivery	al., "Identification of the Pathway of : Light and Ultrastructure Studies Using Pharm. Res., 11(2):251-256 (1994).		
	AU3	Langkjaer, L., et al., "Ion Vitro: Effects of Insulin C Release, 51:47-56 (1998).	tophoresis of Monomeric Insulin Analogues In harge and Skin Pretreatment," J . Control.		
	AV3	Chizmadzhev, Y., et al., "E Voltages: Contribution of Ap 843-856 (1998).	lectrical Properties of Skin at Moderate ppendageal Macropores," Biophys. J., 74:		
	AW3	- Laubhicz, M.R., et al., "E.	lectroporation of Mammalian Skin: A ermal Drug Delivery," Proc. Nat. Acad. Sci.		
	AX3	Trausurcz, M.K., et al., "Me	ethods for in Vivo Tissue Electroporation Drug Delivery, 1(2):125-131, (1993).		
	AY3	Gallo, S.A, et al., "Charact Permeabilization of Porcine Biophysical Journal, 72: 280	cerization of Electric-Pulse-Induced Skin Using Surface Electrodes," 05-2811 (1997).		
	A23	Vanbever, R., et al., "In vi Skin after High-Voltage Puls Physiol., 11:23-34 (1998).	vo Noninvasive Evaluation of Hairless Rat se Exposure," Skin Pharmacol. Appl. Skin		
	AR4	Vanbever, R., et al., "Trans of Analgesia Using Skin Elec 225-235 (1998).	dermal Delivery of Fentanyl: Rapid Onset troporation," J. Controlled Release, 50:		
	AS4	Across the Stratum Corneum T	troporation Causes Molecular Transport hrough Localized Transport Regions," J. Proceedings, 3:159-165 (1998).		
	AT4	Fransdermal Voltage and Flux	troporation: Rapid Measurements of the of Four Fluorescent Molecules Show a ear 50 V," J. of Pharm. Sci., 87(11):1368-		
	AU4	VanBever, R., et al., "Comparison of the Effects of Short, High-voltage and Long, Medium-Voltage Pulses on Skin Electrical and Transport Properties," J. Controlled Release, 69:35-47, (1999).			
	AV4				
EXAMI	NER	/Bhisma Mehta/	ATE CONSIDERED 06/01/2009		

Receipt date: 06/16/2004

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH and Patternark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUH 1

Substitute for form 1449A/PTO Complete if Known Application Number 10/800,587 ENFORMATION DISCLOSURE Filing Date March 15, 2004 STATEMENT BY APPLICANT First Named Inventor James C. Weaver 3763 Art Unit 6 2004 S (use as many sheets as necessary) Examiner Name Not Yet Assigned

She		7,	of	8	Attorney Docket Number	003979-00002
DADE				U.S.	PATENT DOCUMENTS	
		OTHER DO	CUMEN	NTS (Including A	uthor, Title, Date, Per	rtinent Pages, Etc.)
i	AW4	Prausnitz Electropo	, M. orati	R., et al., `on," Biotech	Transdermal Delive nology, 13: 1205-1	ry of Heparin by Skin 209 (1995).
	AX4	Heise, H. Infrared (1996).	M., Spec	"Non-Invasive troscopy: Sta	Monitoring of Met te of the Art," Ho	abolites Using Near rm. Metab. Res., 28:527-534
2	AY4	Validatio Electroch	n of emic	the Wick Tec	hnique as a Refere	eous Glucose Concentration: nce for Implanted ic Dogs," Diabetologia,
	AZ4	Technique	: An	Experimental	se Determination B Study Using A Gel 911-1922, (1993).	y a Pulsed Photoacoustic atin-Based Tissue Phantom,"
P	AR5	Tamada, J Using Non 1202 (199	inva	et al., "Mea sive Transder	surement of Glucos mal Extraction," N	e in Diabetic Subjects ature Medicine, 1(11):1198-
A	185	on ISFET	Gluc	l., "Transcut ose Sensor an gng., 6(4):26	d Studies on Diabet	se Monitoring System Based tic Patients," Frontiers
А	AT5	Berger, A Near-infr (1997).	.J., ared	"Feasibility Raman Spectro	of Measuring Blood oscopy," Spectochin	d Glucose Concentration by n. Acta, 53(Part A):287-292
A		Neonates a Exchanger	and] vs.	Infants: A Com a Heated Hum	mparative Study of	Mechanically Ventilated a Heat and Moisture Fast-response Capacitive 5-1760 (1997).
Α	V5	Ohhashi, (et al 9-461	l., "Human Per (1998).	espiration Measurem	ment," Physiol. Meas.
A		Transport	Thro	ough Human Sti	catum Corneum Durin	at Molecules and Small Ion ag High-Voltage Pulsing: Biophys. Chem.,58:185-
A		Stratum Co	orneu	l., et al., "I m During High 85(12):1363-13	1 Voltage and Low V	Transport Across Human oltage Exposures," J.
A	Weaver, J.C., et al. "Theory of Electrical Creation of Aqueous Pathways Across Skin Transport Barriers," Advanced Drug Delivery Reviews, 35(1):21-39, (1999).				eation of Aqueous Pathways rug Delivery Reviews,	
A	Gowrishankar, T.R., et. al., "Spatially Contrained Localized Transport Regions Due to Skin Electroporation," J. controlled Release, 60(1): 101-110 (1999).				ained Localized Transport rolled Release, 60(1):	
EXAMINER	-	/Bhisma Meh	ta/		DATE CONSIDERED 06	/01/2009

Receipt date: 06/16/2004

ALL REPERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BM/Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known **Application Number** 10/800,587 Filing Date March 15, 2004 First Named Inventor James C. Weaver Art Unit 3763 Examiner Name Not Yet Assigned Attorney Docket Number 003979-00002

Substitute for form 1449A/PTO PNEORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

ACT	and the second s	O03979-00002					
	OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pages, Etc.)					
AR6	Hikima, T., et al., "Effe Metabolism of Prednisolon (1998).	ct of Ultrasound Application on Skin e 21-Acetate," <i>Pharm. Res., 15(11)</i> :1680-1683					
AS6	Mu, b., et al., "Delects (Wu, J., et al., "Defects Generated in Human Stratum Corneum Specimens by Ultrasound," <i>Ultrasound in Med. & Biol. 24(5):</i> 705-710 (1998).					
AT6	Henry, S., et al., "Micron Transdermal Drug Delivery,	fabricated Microneedles: A Novel Approach to ," J. Pharm. Sci. 87(8):922-925 (1998).					
AU6	Miyajima, et al., "Effect Stage Diffusion-Controlled J. Controlled Rel. 61(3):2	of Polymer/Basic Drug Interaction on the Two Release from a Poly(L-lactic Acid) Matrix," 295-304 (1999).					
AV6	Model Proteins Through and	anisms Controlling Diffusion and Release of From Partially Esterified Hyaluronic Acid Rel. 61(3):267-279 (1999).					
AW6	Hyaluronic Acid: Synthesis	Controlled Chemical Modification of s, Applications, and Biodegradation of Control. Release 53:93-103 (1998).					
AX6	Koo, T-W., et al., "Reagentless Blood Analysis by Near-Infrared Raman Spectroscopy," Diabetes Tech. Therapeut., 1(2):153-157 (1999).						
AY6	Berger, A.J., et al., "Mu Raman Spectroscopy," Appl.	lticomponent Blood Analysis by Near-Infrared Optics 38(13):2916-2926 (1999).					
AZ6	Powderject Delivery of Tes	ffects of Payload Per Unit Area on Dermal stosterone to Conscious Rabbits," Proceed. Bioact. Mater., 25:595-596 (1998).					
AR7	Uchida, M.,et al., "Transd Helios™ Gun System," Proce Mater., 25:575-576 (1998).	ermal Microparticle Delivery by a Supersonic. ed. Int'l. Symp. Control. Rel. Bioact.					
AS7	Sage, B.H., Jr., "Iontopho: Percutaneous Penetration Es	resis" CRC Press, Inc., Chapter 15.1 nhancers 351-368 (1995).					
AT7	Weaver, J.C., and Langer, I Aqueous Pathways: an Approx in Dermatology, 33:1-10 (19	R., "Electrochemical Creation of Large ach to Transdermal Drug Delivery," Progress 1999).November 26, 2001					
AU7							
AV7	Scott, E.R., et al., "Direct Imaging of Ionic Pathways in Stratum Corneum Using Scanning Electrochemical Microscopy," Solid State Ionics, 53-56(Part 1):176-183 (1992).						
AW7	November 26, 2001	rochemical Creation of Large Aqueous Pathways: an ery," Progress in Dermatology, 33: 1-10 (1999)					
01EXAMINE	/Bhisma Mehta/	DATE CONSIDERED 06/01/2009					